Status:
COMPLETED
Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections
Lead Sponsor:
Medical University of Vienna
Collaborating Sponsors:
Medical Scientific Fund of the Mayor of Vienna
Conditions:
Disseminated Intravascular Coagulation
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For example, coagulation abnormalities are nearly universal in septic patients. Coagulation disorders have also bee...
Eligibility Criteria
Inclusion
- Admission to ICU
- Clinical signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2
- Neutrophil-Lymphocyte Ratio (NLR) \>3
Exclusion
- Intake of oral anticoagulants or any kind of parenteral therapeutic anticoagulation prior to ICU admission
- Congenital coagulation disorder
- Treatment with Prothrombin complex concentrate (F. II, VII, IX, X) or activated Prothrombin complex within past 48 hours
- Treatment with recombinant factor VIIa (e.g. eptacog alfa) within past 48 hours
- Treatment with recombinant protein C within past 48 hours
- Active bleeding
- Acute myocardial infarction
- HIV infection
- Chronic pancreatitis
- Liver cirrhosis
Key Trial Info
Start Date :
April 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2021
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04356144
Start Date
April 15 2020
End Date
February 1 2021
Last Update
March 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Vienna
Vienna, Austria, 1090